SAN LEANDRO, Calif.–Alpha Innotech (OTCBB:APNO – News), a leading provider of innovative bioimaging solutions for the life science research market, announced today that it has begun shipment of RED™, its newest gel imaging system.
Designed to take advantage of the burgeoning global market for personal laboratory instruments, the RED personal gel imager combines touch screen controls with advanced imaging technology and an integrated onboard computer, all in a uniquely compact footprint.
RED’s scientific-grade sensor and innovative optical design provides the flexibility critical to imaging the growing list of fluorescent labels found in a typical laboratory. RED’s integrated transillumination and epi illumination sources combined with its three position filter wheel are designed for exciting and imaging a wide variety of UV fluorescent labels commonly used in stained DNA and protein gels, such as Ethidium Bromide, SYBR® Green, SYBR® Safe and Hoechst Blue. RED also excels at imaging white light applications such as coomassie and silver stained protein gels. Images can be saved to a USB memory stick or printed directly to a digital thermal printer for archiving in the user’s lab notebook.
RED was designed for maximum ease of use. From its simple installation to its intuitive user interface, this system is plug-and-play. “Most gel imaging systems on the market require a company representative to perform the installation and provide individual training,” commented Lawreen Asuncion, Associate Product Manager. “With RED, the user can simply pull the instrument out of the box, plug in the power cord, turn it on and start imaging. With all imaging controls at their fingertips, users can quickly acquire an image with just a few taps on the touch screen. The instrument is so easy to use that no training is needed for broad gel based applications.”
“Alpha Innotech has long been a market leader in high end chemiluminescence and fluorescence imaging workstations,” stated Sia Ghazvini, Vice President of Marketing and Business Development. “With RED, we have taken our advanced technology and made it simple and intuitive to use and integrated all system components into a compact footprint. RED provides a powerful yet cost effective solution that we believe will enable more labs worldwide to adopt digital gel documentation systems.”
For more information on RED please visit www.alphainnotech.com. The instrument and supporting reagents and consumables are also available for purchase online at Alpha Innotech’s website.
About Alpha Innotech Corp.
Founded in 1992 and with over 10,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide. More information on Alpha Innotech can be found at the Company’s website www.alphainnotech.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, the Company’s ability to obtain additional financing if needed, the timing of the introduction and success of new products, and the Company’s growth prospects, that could cause actual results to differ materially from those anticipated or planned by these forward-looking statements. Please also refer to the risk factors described in our filings with the Securities and Exchange Commission, including our recent Form 10-KSB and Forms 10-QSB filed with the Securities and Exchange Commission. We do not intend to update the forward-looking information contained in this news release except as required by law.